The major goal of the Tumour Immunology Laboratory is to obtain a deeper understanding of the mechanisms by which an immune response to tumours may be generated, augmented and applied to the inhibition of tumour growth.
The members of this laboratory share the expectation that such insight will be applicable to the treatment and/or prevention of cancer.
Group Leader: Professor Rajiv Khanna
- Linda Jones, Scientific Technical Officer
- Professor Denis Moss, Honorary SPRF
- Dr Corey Smith, Team Head
- Dr Archana Panikkar, Research Officer
- Dr Vijayendra Dasari, Research Officer
- Dr Gary Brooke, Clinical Project Manager
- Dr Michelle Neller, Clinical Trials Manager
- Dr Katherine Matthews, Clinical Trials Coordinator
- Pauline Crooks, Research Assistant
- Leone Beagley, Research Assistant
- Lea Lekieffre, Research Assistant
- Sweera Rehan, Research Assistant
- George Ambalathingal Thomas, PhD Student
- Dillon Corvino, PhD Student
- Kristine Hua, PhD Student
Relevant Publications and Patents or Patent ApplicationS for EBV IMMUNOTHERAPY
Smith, C. and KHANNA, R. Adoptive therapy for EBV-induced cancers: driving success with PTLD to other EBV-derived tumours. Immunotherapy (2015) 7(5), 563-572.
Smith, C. and KHANNA, R. The Development of Prophylactic and Therapeutic EBV Vaccines. Curr Top. Micrbiol. Immunol. (2015) 391: 455-473.
Pender, M. and KHANNA, R. Epstein–Barr virus-specific adoptive immunotherapy: a new horizon for multiple sclerosis treatment? Immunotherapy (2014) 6(6), 659–661.
Muratt, P., Zhong, J., Lekieffre, L., Cowieson, N.P., Clancy, J.L., Preiss, P., Balasubramaniant, S, KHANNA, R., and Tellam, J.T. RNA G-quadruplexes regulate Epstein-Barr virus encoded nuclear antigen 1 mRNA translation. Nature Chem. Biol. (2014) 10: 358–364.
Pender, M., Csurhes P, Beagley, L, Kaye, D., Meenakshi, M., Coulthard, A. Burrows, S.R. and KHANNA, R. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Multiple Sclerosis J (2014) 6: 659-661. (IF: 4.472: Citations: 8)
Smith, C., Tsang,,J., Beagley, L., Chua, C., Lee, V., Li, V., Moss, D. J., Coman, W., Chan, K.H., Nicholls, J., Kwong, D. and Khanna, R. Effective treatment of metastatic forms of Epstein-Barr virus associated nasopharyngeal carcinoma with a novel adenovirus based adoptive immunotherapy. Cancer Res. (2012) 72(5):1116-1125.
Smith C, KHANNA R. A new approach for cellular immunotherapy of nasopharyngeal carcinoma. OncoImmunology (2012)1(8):1440-1442
Smith, C. and KHANNA, R. Immune regulation of human herpesviruses and its implications for human transplantation. Am. J. Transplantation (2013) 13:9-23.
Duraiswamy, J., Sherritt, M., Thomson, S., Tellam, J., Cooper, L., Connolly, G., Bharadwaj, M., KHANNA, R. Therapeutic LMP1 polyeptiope vaccine for Hodgkin’s Disease and Nasopharyngeal Carcinoma. Blood (2003) 101: 3150-3156.
Duraiswamy, J., Bharadwaj, M., Tellam, J., Connolly, G., Cooper, L., Moss, D. J., Thomson, S., Yotnda, P., and KHANNA, R. Induction of therapeutic T cell responses to subdominant tumour-associated viral oncogene following immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Research (2004) 64:1483-1489.
KHANNA, R. Moss, D. and Gandhi, M. Application of emerging therapeutic strategies for EBV-associated malignancies. Nature Clinical Practice-Oncology. (2005) 2, 138-149.
Gandhi, M. K., Lambley, E. Burrows, J., Dua, U., Elliott, S., Shaw, P., Miles, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J.F., KHANNA, R., Plasma Epstein-Barr virus DNA is a biomarker for EBV-positive Hodgkin lymphoma. Clin. Cancer Res. (2006)12: 460-464.
Gandhi, M.K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., and KHANNA, R. Expression of LAG-3 by tumor-infiltrating lymphocytes is co-incident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patient. Blood (2006) 108(7):2280-2289.
Smith, C., Cooper, L., Burgess, M., Rist, M., Webb, N., Lambley, E., Tellam, J., Marlton, P., Seymour J.F., Gandhi, M., and KHANNA, R. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J. Immunol. (2006) 177(7):4897-906.
Gandhi, M.K., Moll1, G., Dua, U., Lambley, E., Ramuz, O., Smith, C., Gill, D., Marlton, P. Seymour, J. & KHANNA, R. Galectin-1 mediated suppression of EBV-specific T-cell immunity in classical Hodgkin’s Lymphoma. Blood (2007) 110: 1326-1329.
KHANNA, R., Bell, S., Sherritt, M., Galbraith, A., Burrows, S. R., Rafter, L., Clarke, B., Slaughter, R., Falk, M. C., Douglas, J., Willams, T., Moss, D. J. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with post-transplant lymphoproliferative disease. Proc. Natl. Acad. Sci. (USA) (1999) 96:10391-10396
International Patent on Polyepitope Technology (Patent number WO9603144)
International Patent on EBV cytotoxic T cell epitopes (Patent number WO974544)
International Patent on cytotoxic T cell from EBV oncogene LMP1 (Patent number WO9902550)
International Patent Application on LMP-based polyepitope (Patent number WO 2004/041849 A1)
Relevant Publications and International Patent Applications for CMV immunotherapy and vaccine development
Crough T and Khanna, R. Immunobiology of Human Cytomegalovirus: From bench to bedside. Clinical Microbiology Reviews (2009) 22: 76-98.
Pierucci, P., Malouf, M., Glanville, A.R., Begley, L., Smith, C. and Khanna R. Novel Autologous T-cell therapy for drug resistant CMV disease after lung transplantation. J. Heart Lung Transplant (2016) http://dx.doi.org/10.1016/j.healun.2015.12.031
Holmes-Liew C.L., Holmes M., Beagley, L., Hopkins, P., Chambers, D., Smith, C. and KHANNA, R. Adoptive T-cell immunotherapy for treatment of Ganciclovir-resistant CMV disease after lung transplantation.Clin Transl Immunology (2015) 4(3), e35. doi: 10.1038/cti.2015.5.
Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, Jones L, Crough T, Dasari V, Klein K, Smalley A, Alexander H, Walker DG, Khanna R. Autologous T cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma. Cancer Res. (2014) 74: 3466-3476
Schuessler, A., Walker, D.G. and KHANNA, R. Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment. OncoImmunology (2014) 3, e29381.
Schuessler, A., Walker, D.G. and KHANNA, R. Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Frontiers in Oncology (2014) 4:275 doi: 10.3389/fonc.2014.00275
Dasari, V., Smith, C., Schuessler, A., Zhong, J. and KHANNA, R. Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity. Hum. Vaccin. Immunother. (2014) 10:4, 1064–1077.
KHANNA, R. and Smith. C. Cellular immune therapy for viral infections in transplant patients. Indian J Med Res (2013) 138: 796-807.
Tey, S.K., KHANNA, R. Host immune system strikes back: Autophagy-mediated antigen presentation bypasses viral blockade of the classic MHC class I processing pathway. Autophagy (2012) 8:12, 1839–1841
Hill GR, Tey SK, Beagley L, Crough T, Morton JA, Clouston AD, Whiting P, KHANNA, R. Successful Immunotherapy of HCMV Disease Using Virus-Specific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient. Am. J. Transplant (2010) 10: 173-179
Zhong J, KHANNA, R. Delineating the role of CD4+ T cells in the activation of CMV-specific immune responses following immunization with Ad-gBCMVpoly vaccine: implications for vaccination of immunocompromised individuals. J Gen Virol. (2010) 91: 2994 – 3001
Dasari, J., Smith, C., Zhong, J., Scott, G., Rawlinson, W., KHANNA, R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J. Gen. Virol. (2011) 92: 1021-1031
Crough, T., Beagley, L., Smith, C., Jones, L., Walker, D.G., and KHANNA, R. Ex vivo functional analysis and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol. Cell Biol. (2012) 90: 872-880
Tey, S.K., Kennedy, G.A., Cromer, D., Davenport, M.P., Walker, S., Jones, L.I., Crough, T., Durrant, S.T., Morton, J.A., Butler, J.P., Misra, A.K., Hill, G.R. and KHANNA, R. Clinical assessment of anti-viral CD8+ T cell immune monitoring to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS ONE (2013) 8: e74744.
International Patent Application on novel HCMV T cell epitopes (Patent application number: AU2002312654)
International Patent Application on HCMV vaccine formulation (Patent application number: AU20040906783)
Smith, C., and KHANNA, R. Nasopharyngeal Carcinoma Immunotherapy: Current Strategies and Perspectives (2012) In Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology Ed: Dr. Pierre Busson. ©2012 Landes Bioscience and Springer Science+Business Media pp173-186.
Smith, C and KHANNA, R. Generation of Cytotoxic T Lymphocytes for Immunotherapy of EBV-Associated Malignancies (2010) In Immunotherapy of Cancer, Methods in Molecular Biology, Ed: P Yotnda. DOI 10.1007/978-1-60761-786-0_3 Springer Science+Business Media, LLC.
Smith, C., and KHANNA, R. Polyepitope Vaccines for Human Cancers (2007). In Cancer Vaccines and Tumor Immunity, Ed: Hodge, J., Johnson, B. and Orentas, R. John Wiley and Sons, Inc. Hoboken, NJ. pp69-78.
Moss, D. J., Burrows, R. and KHANNA, R., Immunobiology of Epstein-Barr virus: (2007) in Human herpesviruses: Biology, Therapy and Immunoprophylaxis Eds:Ann M. Arvin, G. Campadielli-Fume, B. Roizman, R. Whitley & K. Yamanishi pp882-892.
Morgan, A. J. and KHANNA, R., Epstein-Barr virus: Section VI: Vaccines and Immunotherapy (2007) in Human herpesviruses: Biology, Therapy and Immunoprophylaxis Eds:Ann M. Arvin, G. Campadielli-Fume, B. Roizman, R. Whitley & K. Yamanishi pp.1265-1277
Moss, D. J., Burrows, S. R. and KHANNA, R. Vaccine Based Approaches: (2005) in Infection, Pathogenesis, Molecular Biology and Control of Epstein-Barr virus Edited by Erle S. Robertson. Publisher Horizon Press pp 253-267.
The major goals of the Tumour Immunology Laboratory are to obtain a deeper understanding of the mechanisms by which an immune response to tumours may be generated, augmented and applied to the inhibition of tumour growth. The members of this laboratory share the expectation that such insight will be applicable to the treatment or prevention of cancer. Some ongoing studies include:
If you wish to apply for QIMR Berghofer's student program,
click here for more information.